Dupixent shows potential as a treatment for atopic dermatitis, alopecia and vitiligo, targeting shared immune pathways for ...

Integrative approaches targeting neurological and immune pathways may help break the itch–scratch cycle in atopic dermatitis, improving pruritus, stress, sleep, and patient outcomes.

Incyte Corporation (($CC:INCY.CUR)) announced an update on their ongoing clinical study. Incyte Corporation is conducting a Phase 3b clinical ...

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a Phase 1 clinical trial titled ‘A PHASE 1, ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

For patients with skin of color and atopic dermatitis (AD), lebrikizumab is efficacious and safe, according to a study ...

Jiangsu Vcare Pharmatech Co., Ltd. (Jiangsu Vcare) announced that it has entered into an exclusive strategic partnership with ...

Patients with moderate to severe and severe alopecia areata have a greater burden of comorbid atopic dermatitis than those with mild alopecia areata.

Apogee Therapeutics recently reported positive 16-week results from its APEX Phase 2 Part A trial, with APG777 meeting all primary and key secondary endpoints in moderate-to-severe atopic dermatitis ...

USA: Atopic eczema (AE), including AE severity, is linked with a decreasing lymphocyte count, regardless of the use of the ...

Individuals presenting with one of several immune-mediated skin diseases may also have a substantially higher risk for keratoconus (KC), according to a large multicenter investigation published in ...

Four out of 10 eczema patients struggle with sleep, and they may not volunteer that information unless you ask.